Breast Cancer Metastatic Clinical Trial
Official title:
A Randomized, 2-Arm, Open-Label, Ph-II Study of Abemaciclib Combined With ET w/ or w/o CT With Paclitaxel as 1L in Patients With Unresectable Locally Advanced or Metastatic HR(+)/HER2(-) BC With Aggressive Disease Criteria
This is a multicenter, randomized, 2 arm, open label, phase II study. It is designed to compare the efficacy and safety of abemaciclib combined with ET (letrozole or fulvestrant) versus a short course with induction chemotherapy with paclitaxel followed by maintenance therapy with abemaciclib combined with ET (letrozole or fulvestrant) in patients with previously untreated, unresectable locally advanced, or metastatic HR positive/HER2 negative breast cancer with aggressive disease criteria.
The ABIGAIL study aims to provide consistent evidence that the combination of abemaciclib with ET -consisting of letrozole or fulvestrant-as first-line regimen is non-inferior to the optimal first-line chemotherapy -consisting of weekly paclitaxel-in terms of early ORR after the first 12 weeks of treatment in patients with HR-positive/HER2-negative ABC and at least one feature of aggressive disease associated with poor prognosis. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04123704 -
Sitravatinib in Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04509596 -
DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04122469 -
The Role of Stereo-tActic BoDy RadIotherApy iN Oligo-Progressive MalignanT Disease
|
N/A | |
| Completed |
NCT03045653 -
Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer
|
Phase 2 | |
| Terminated |
NCT03322215 -
HR+/HER2- Advanced Breast Cancer and Endocrine Resistance
|
Phase 2 | |
| Active, not recruiting |
NCT04059484 -
Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT04368442 -
Cohort Study of Patients With HER2-negative MBC and BRCA 1/2 Pathogenic Mutation
|
||
| Terminated |
NCT03709082 -
Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT03642990 -
NR in Chemo-induced Peripheral Neuropathy
|
Phase 2 | |
| Terminated |
NCT01876251 -
A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04483505 -
Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.
|
Phase 1 | |
| Recruiting |
NCT03086785 -
Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer
|
Phase 2 | |
| Terminated |
NCT04197999 -
A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT03638765 -
Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT06100874 -
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After progrEssion on ENhertu (SATEEN)
|
Phase 2 | |
| Completed |
NCT05609903 -
Atezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast Cancer
|
||
| Active, not recruiting |
NCT04597580 -
Personalised Disease Monitoring in Metastatic Breast Cancer
|
||
| Completed |
NCT05301530 -
Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.
|
Phase 1 | |
| Active, not recruiting |
NCT03328884 -
Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients
|
Phase 2 | |
| Recruiting |
NCT05837533 -
Multicenter Study to Evaluate a Systematized Communication Model for Breast Cancer Patients
|
N/A |